Asymchem(002821) 海通证券·2025-04-02 03:45Investment Rating - The investment rating for the company is "Outperform the Market" [2] Core Views - The report highlights that the company has achieved steady revenue growth in its emerging business segments and maintains a strong order backlog, indicating a positive long-term development outlook [4][11] Summary by Sections Financial Performance - In 2024, the company's operating revenue was 5.805 billion yuan, a year-on-year decrease of 25.82%. Excluding the impact of large orders from the previous year, revenue grew by 7.40%. The net profit attributable to the parent company was 949 million yuan, down 58.17% year-on-year. In Q4 2024, operating revenue reached 1.664 billion yuan, a year-on-year increase of 15.41%, with net profit of 239 million yuan, up 306.48% [4][6] Business Segment Performance - Small molecule CDMO business generated revenue of 4.571 billion yuan, with an 8.85% year-on-year increase after excluding large orders. The gross margin for this segment was 47.95%. The company delivered 48 commercial projects and added 8 new commercial projects [7] - Emerging business revenue was 1.226 billion yuan, a 2.25% year-on-year increase. The gross margin for this segment was 21.67%, with an upward trend expected in the second half of 2024 [8] - Clinical CRO business saw a slight revenue decline, with 197 new projects initiated. The company is currently managing 269 clinical research projects [8] - The biopharmaceutical CDMO business focused on ADC projects, with a revenue increase of 13.91% and a significant order backlog [8] Order Backlog and Market Expansion - The company reported a 20% year-on-year increase in new orders, with a total order backlog of 1.052 billion USD, reflecting strong demand from the US and European markets [11] - The company is expanding its global production capacity, with new facilities in Europe and ongoing projects in the US, contributing to revenue growth from these regions [11] Financial Forecast - The company expects EPS of 3.03, 3.60, and 4.42 yuan for 2025, 2026, and 2027 respectively. The report suggests a reasonable valuation range of 90.87 to 106.01 yuan based on a PE ratio of 30-35 for 2025 [11][13]